TVRD vs UIS Comparison

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Unisys Corp is engaged in the provision of technology solutions for clients across the government, financial services, and commercial markets. It operates through three business segments: Digital Workplace Solutions (DWS),Cloud, Applications & Infrastructure Solutions (CA&I), and Enterprise Computing Solutions (ECS). DWS provides workplace solutions featuring intelligent workplace services, proactive experience management and collaboration tools to support business growth. CA&I which provides digital transformation in the areas of cloud migration and management. ECS which provides solutions that harness secure, high-intensity enterprise computing and enable digital services through software-defined operating environments. Majority of revenue is from ECS segment.